27,306 views
http://www.medicinaeinformazione.com/ / medicinaeinformazione COPD, chronic obstructive pulmonary disease is a progressive disease, characterized by a deterioration of lung function that over time compromises breathing and causes serious limitations even in performing simple daily tasks. Among the main critical issues for a correct treatment of COPD is certainly the fact that it is a disease still largely underestimated and underdiagnosed, but also the poor therapeutic adherence, which does not exceed 30%. Timely treatment, more effective drugs and simplification of therapy are still unmet needs of patients, therefore, and an important therapeutic innovation for the over three and a half million Italians living with COPD is represented by the approval in Italy by AIFA of the first triple fixed extrafine combination, administered in a single inhaler, the result of research by Chiesi Italia, a therapy that combines a steroid inhaler and two bronchodilators in a single device, allowing to reduce the number of exacerbations, improve breathing capacity and therefore the quality of life, and at the same time improve therapeutic adherence thanks to the simplicity of administration. During the press conference dedicated to the new therapy for COPD we interviewed: Antonio Spanevello, University of Insubria - Maugeri Institutes Alberto Papi, University of Ferrara Paola Perna, Catholic University of the Sacred Heart of Milan Marco Zibellini, Medical Director Chiesi Farmaceutici